{"id":53273,"date":"2023-01-25T12:02:19","date_gmt":"2023-01-25T11:02:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/"},"modified":"2023-01-25T12:02:19","modified_gmt":"2023-01-25T11:02:19","slug":"ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/","title":{"rendered":"KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology"},"content":{"rendered":"
\n

LEXINGTON, Mass.–(BUSINESS WIRE)–KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics platform, announced today that Ono Pharmaceutical Co., Ltd. (\u201cONO\u201d), has acquired multiple research-stage DNA damage response (DDR) programs identified using KSQ\u2019s CRISPRomics platform technology. All the programs are novel and have the potential to become first-in-class therapies.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThis acquisition of multiple research-stage oncology programs by ONO is further validation of the power of our platform to identify novel oncology targets and develop potential first-in-class programs,\u201d said Qasim Rizvi, Chief Executive Officer of KSQ. “This is an important transaction for KSQ, enabling us to focus on our other programs. We look forward to watching ONO\u2019s progress as they advance these programs toward clinical studies.”\n<\/p>\n

\n\u201cONO appreciates the ability of KSQ’s CRISPRomics platform technology to discover novel therapeutic targets with high selectivity for cancer cells,\u201d said Toichi Takino, Senior Executive Officer \/ Executive Director, Discovery & Research of ONO. \u201cThrough this acquisition agreement, we expect that the programs acquired from KSQ will lead to the creation of innovative medicines that will help treat cancer patients.\u201d\n<\/p>\n

\nUnder the terms of the agreement, ONO will provide KSQ a double-digit million upfront and potential near-term milestone payments with potential long-term value into the triple-digit millions as well as royalties based on net sales.\n<\/p>\n

\nAbout KSQ Therapeutics<\/b>\n<\/p>\n

\nKSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates to treat cancer and autoimmune disease across multiple drug modalities, including targeted therapies, adoptive cell therapies, and immunotherapies. KSQ’s proprietary CRISPRomics\u00ae<\/sup> discovery engine enables genome-scale, in vivo<\/i> validated, unbiased drug discovery across broad therapeutic areas. For more information, please visit the company’s website at www.ksqtx.com<\/a> and follow @ksq_tx<\/a> on Twitter.\n<\/p>\n

\nAbout Ono Pharmaceutical Co., Ltd.<\/b>\n<\/p>\n

\nOno Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company\u2019s website at https:\/\/www.ono-pharma.com\/en<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Cory Tromblee
\n
cory@scientpr.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LEXINGTON, Mass.–(BUSINESS WIRE)–KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics platform, announced today that Ono Pharmaceutical Co., Ltd. (\u201cONO\u201d), has acquired multiple research-stage DNA damage response (DDR) programs identified using KSQ\u2019s CRISPRomics platform technology. All the programs are novel and have the potential … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53273","6":"format-standard","7":"category-industry"},"yoast_head":"\nKSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass.–(BUSINESS WIRE)–KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics platform, announced today that Ono Pharmaceutical Co., Ltd. (\u201cONO\u201d), has acquired multiple research-stage DNA damage response (DDR) programs identified using KSQ\u2019s CRISPRomics platform technology. All the programs are novel and have the potential ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-25T11:02:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230125005277\/en\/1695291\/21\/KSQ-logo-color_RegTM_copy.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology\",\"datePublished\":\"2023-01-25T11:02:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/\"},\"wordCount\":389,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230125005277\\\/en\\\/1695291\\\/21\\\/KSQ-logo-color_RegTM_copy.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/\",\"name\":\"KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230125005277\\\/en\\\/1695291\\\/21\\\/KSQ-logo-color_RegTM_copy.jpg\",\"datePublished\":\"2023-01-25T11:02:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230125005277\\\/en\\\/1695291\\\/21\\\/KSQ-logo-color_RegTM_copy.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230125005277\\\/en\\\/1695291\\\/21\\\/KSQ-logo-color_RegTM_copy.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/","og_locale":"en_US","og_type":"article","og_title":"KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology - Pharma Trend","og_description":"LEXINGTON, Mass.–(BUSINESS WIRE)–KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics platform, announced today that Ono Pharmaceutical Co., Ltd. (\u201cONO\u201d), has acquired multiple research-stage DNA damage response (DDR) programs identified using KSQ\u2019s CRISPRomics platform technology. All the programs are novel and have the potential ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-25T11:02:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230125005277\/en\/1695291\/21\/KSQ-logo-color_RegTM_copy.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology","datePublished":"2023-01-25T11:02:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/"},"wordCount":389,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230125005277\/en\/1695291\/21\/KSQ-logo-color_RegTM_copy.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/","url":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/","name":"KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230125005277\/en\/1695291\/21\/KSQ-logo-color_RegTM_copy.jpg","datePublished":"2023-01-25T11:02:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230125005277\/en\/1695291\/21\/KSQ-logo-color_RegTM_copy.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230125005277\/en\/1695291\/21\/KSQ-logo-color_RegTM_copy.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ksq-therapeutics-announces-ono-pharmaceutical-co-ltd-is-acquiring-multiple-research-stage-oncology-programs-identified-with-ksqs-crispromics-platform-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53273"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53273\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}